ライフサイエンスコーパス: euphoria

1 d amphetamine produced positive symptoms and euphoria.

2 ntribute to psychosis, thought disorder, and euphoria.

3 sponses, including cognitive alterations and euphoria.

4 iating their effects in both pain relief and euphoria.

5 e to cocaine and/or an enhanced induction of euphoria.

6 commonly dizziness (59%), paresthesia (34%), euphoria (30%), and hypoesthesia (30%).

7 binoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment.

8 nd the type II alcoholics reported increased euphoria and a greater likelihood of drinking.

9 PG also showed blunted amphetamine-induced euphoria and alertness compared with HV.

10 ing order, providing self-report measures of euphoria and arousal at regular intervals.

11 ain networks associated with cocaine-induced euphoria and cocaine-induced craving.

12 ed brain circuitry mediating cocaine-induced euphoria and craving using functional MRI (fMRI).

13 ive and subjective opioid effects, including euphoria and drug liking, in opioid-experienced adults.

14 ATEMENTCannabis sativa, or marijuana, causes euphoria and exerts a wide range of medicinal benefits.

15 Thus, MDMA increased euphoria and feelings of sociability, perhaps by reducin

16 in coupled receptor that mediates analgesia, euphoria and other important central and peripheral neur

17 (SSRT) reported greater amphetamine-induced euphoria and stimulation than those with shorter SSRT.

18 at least one cardinal mania criterion (i.e., euphoria and/or grandiosity) to ensure differentiation f

19 rcement, subjectively linked to drug-induced euphoria, and negative reinforcement, subjectively linke

20 increases receptor affinity, alcohol-induced euphoria, and risk for alcohol use disorders.

21 ve effects on thought disorder, arousal, and euphoria; and (3) amphetamine and ketamine had less-than

22 unner's high as a sudden pleasant feeling of euphoria, anxiolysis, sedation, and analgesia.

23 iting reactions were neurologic (somnolence, euphoria, ataxia) and associated with the infusion.

24 cannabinoid or opioid receptor blockage, and euphoria cannot be studied in mouse models.

25 SA did not produce euphoria, cognitive deficits, or changes in vital signs.

26 d not change MOR binding, although increased euphoria correlated with decreased receptor binding.

27 ll number of study participants, showed that euphoria, disinhibition, and nighttime behaviors were si

28 rus during the inhibition task reported more euphoria during the amphetamine sessions.

29 eart rate and blood pressure and feelings of euphoria (eg, 'High' and 'Like Drug').

30 ization, tolerance, physical dependence, and euphoria/elation.

31 a single dose of the drug is associated with euphoria, elevated self-confidence, and heightened senso

32 After a transitory period of euphoria engendered by the improved prognosis of pneumoc

33 ocaine-induced fear compared with those with euphoria had greater increases in left amygdalar CBF.

34 (m-CPP) produced increases in activation and euphoria in depressed patients with SAD, but not in pati

35 sm whereby cocaethylene produces a decreased euphoria in humans compared to cocaine.

36 nt monoamine releaser that produces an acute euphoria in most individuals.

37 subjects reported subjective stimulation and euphoria in response to cocaine administration.

38 e to tactile stimuli, gustatory stimuli, and euphoria-inducing drugs is consistent with a contributio

39 ate positively with fear and negatively with euphoria intensity.

40 Mania is accompanied by symptoms of euphoria, irritability, or excitation, whereas depressio

41 People typically drink alcohol to induce euphoria or reduce anxiety, and they frequently drink in

42 behavioral states, including disinhibition, euphoria, or elaborate stereotypies, whereas dopamine de

43 ed phenotype defined by a preference for all euphoria-producing drugs.

44 ced (1) significant increases in "activation-euphoria" ratings only in depressed patients with SAD in

45 The abnormal m-CPP-induced activation-euphoria responses represent a replicated state marker o

46 ess, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusio